Nanosonics Ltd (ASX: NAN) announced a pleasing piece of news this morning. The company said that trophon2 conforms with the European Union Requirements.
The trophon2 device is the second generation of the trophon system which prevents ultrasound probe cross-infection from occurring. Nanosonics boasts that the trophon device is easy to install, set-up and maintain, all it needs is to be plugged in.
Nanosonics now expects that trophon2 will be launched in Europe, the USA and Canada in the first quarter of the 2019 financial year. Its first-generation device has been popular with many thousands of devices being installed. It operates a “Gillette” model where the user buys the device and pays for high-margin consumables.
The CEO of Nanosonics, Michael Kavanagh, said “This is excellent news that enables Nanosonics to launch trophon2 for customers in both North America as well as Europe in the same time frame.
“The trophon2 delivers a range of exciting new customer focused features including new capabilities that were specifically developed based on feedback from the European market. The new trophon2 is currently being introduced into manufacturing and we look forward to bringing it to market in the first quarter of the 2019 financial year.”
There are other products that Nanosonics is also researching and developing which could be launched over the next couple of years using the same sort of technology. These new devices could be just as big of an opportunity as trophon for Nanosonics.
The products that Nansonics offers are excellent devices, but I find it hard to quantify what a reasonable valuation for the business would be. So for that reason, I am steering clear of Nanosonics shares. Although it could turn into a global healthcare leader in its space like Cochlear Limited (ASX: COH).
Instead of Nanosonics, I’d much rather buy shares of one of these top stocks for my portfolio.
For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..
But knowing which blue chips to buy, and when, can be fraught with danger.
The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."
Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.
The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.
Click here to claim your free report.
Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.